Laurel Wealth Advisors LLC Has $6.83 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Laurel Wealth Advisors LLC lessened its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 0.6% in the second quarter, Holdings Channel reports. The firm owned 21,051 shares of the company’s stock after selling 125 shares during the quarter. Eli Lilly and accounts for about 1.6% of Laurel Wealth Advisors LLC’s investment portfolio, making the stock its 16th largest position. Laurel Wealth Advisors LLC’s holdings in Eli Lilly and were worth $6,825,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cordant Inc. acquired a new position in Eli Lilly and during the first quarter worth about $25,000. Castle Wealth Management LLC acquired a new position in Eli Lilly and during the second quarter worth about $28,000. Horan Securities Inc. raised its stake in Eli Lilly and by 96.0% during the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock worth $32,000 after acquiring an additional 48 shares in the last quarter. Cypress Capital Management LLC WY raised its stake in Eli Lilly and by 300.0% during the second quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock worth $32,000 after acquiring an additional 75 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in Eli Lilly and during the first quarter worth about $33,000. Institutional investors and hedge funds own 82.45% of the company’s stock.

Eli Lilly and Trading Up 0.2 %

Shares of Eli Lilly and stock traded up $0.84 on Thursday, reaching $361.72. 1,993,218 shares of the company’s stock were exchanged, compared to its average volume of 3,419,741. The company has a market capitalization of $343.70 billion, a P/E ratio of 54.31, a price-to-earnings-growth ratio of 2.27 and a beta of 0.36. Eli Lilly and Company has a 52 week low of $231.87 and a 52 week high of $369.80. The firm’s 50-day moving average is $338.86 and its two-hundred day moving average is $321.23. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13.

Eli Lilly and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date is Monday, November 14th. Eli Lilly and’s payout ratio is 58.86%.

Insiders Place Their Bets

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 63,585 shares of the stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $363.94, for a total transaction of $23,141,124.90. Following the transaction, the insider now directly owns 103,158,810 shares in the company, valued at approximately $37,543,617,311.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 63,585 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $363.94, for a total transaction of $23,141,124.90. Following the transaction, the insider now directly owns 103,158,810 shares of the company’s stock, valued at $37,543,617,311.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alonzo Weems sold 656 shares of the company’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $326.23, for a total value of $214,006.88. Following the transaction, the executive vice president now directly owns 6,950 shares in the company, valued at $2,267,298.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 571,297 shares of company stock worth $193,929,777. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several research analyst reports. The Goldman Sachs Group boosted their target price on Eli Lilly and from $281.00 to $313.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 8th. Barclays boosted their price target on Eli Lilly and from $355.00 to $395.00 and gave the stock an “overweight” rating in a report on Wednesday, November 2nd. StockNews.com assumed coverage on Eli Lilly and in a report on Wednesday, October 12th. They set a “buy” rating on the stock. Citigroup boosted their price target on Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Finally, UBS Group upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $335.00 to $363.00 in a report on Thursday, September 22nd. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and currently has a consensus rating of “Moderate Buy” and an average target price of $359.78.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.